Overview

CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies

Status:
Recruiting
Trial end date:
2035-08-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to test whether CD22-CAR T cells can be successfully made from immune cells collected from pediatric and young adult subjects with relapsed/refractory B-cell malignancies (leukemia and lymphoma). Another purpose of this study is to test the safety and cancer killing ability of a cell therapy against a new cancer target (CD22).
Phase:
Phase 1
Details
Lead Sponsor:
Stanford University
Treatments:
Cyclophosphamide
Fludarabine
Fludarabine phosphate